Utility of Microcrystalline Cellulose for Improving Drug Content Uniformity in Tablet Manufacturing Using Direct Powder Compression View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-05

AUTHORS

Shohei Nakamura, Chisato Tanaka, Hiroshi Yuasa, Takatoshi Sakamoto

ABSTRACT

Direct powder compression is the simplest tablet manufacturing method. However, segregation occurs when the drug content is low. It is difficult to assure drug content uniformity in these cases. In this study, we evaluated microcrystalline cellulose (MCC) as a segregation inhibitor in pharmaceutical powders. We assessed the influence of MCC concentration and mixing time on the physical properties of tablets. The tablet formulation comprised acetaminophen, lactose hydrate, cornstarch, MCC (0%, 10%, or 20%), croscarmellose sodium, and magnesium stearate (Mg-St). All powders except Mg-St were premixed for 5, 15, or 25 min. Mg-St was then added and mixed for 5 min to prepare nine pharmaceutical powders. Flowability index and practical angle of internal friction were measured. Tablets were also prepared, and their weight variation, hardness, friability, disintegration time, and drug content variation were evaluated. MCC slightly decreased pharmaceutical powder flowability. Tablet hardness increased and disintegration time decreased with increasing MCC concentration. MCC mixed for ≥ 15 min also significantly lowered drug content variation. A contour plot was prepared to assess the effect of MCC concentration and mixing time on the physical properties of tablets. It was determined that tablets with 50-80 N hardness, ≤ 3.5 min disintegration time, and ≤ 3% drug content variation can be prepared when MCC concentration is 6.5-8.5% and the mixing time is 19-24 min. Therefore, MCC is effective as a segregation inhibitor, and the addition of MCC to tablet formulation improves drug content uniformity. More... »

PAGES

151

References to SciGraph publications

Journal

TITLE

AAPS PharmSciTech

ISSUE

4

VOLUME

20

Identifiers

URI

http://scigraph.springernature.com/pub.10.1208/s12249-019-1365-4

DOI

http://dx.doi.org/10.1208/s12249-019-1365-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112942613

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30903317


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0904", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Engineering", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/09", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Engineering", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Matsuyama University", 
          "id": "https://www.grid.ac/institutes/grid.411613.0", 
          "name": [
            "Department of Pharmaceutical Technology, School of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, 790-8578, Matsuyama, Ehime, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakamura", 
        "givenName": "Shohei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Matsuyama University", 
          "id": "https://www.grid.ac/institutes/grid.411613.0", 
          "name": [
            "Department of Pharmaceutical Technology, School of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, 790-8578, Matsuyama, Ehime, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Chisato", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Showa University", 
          "id": "https://www.grid.ac/institutes/grid.410714.7", 
          "name": [
            "School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, 142-8555, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuasa", 
        "givenName": "Hiroshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Matsuyama University", 
          "id": "https://www.grid.ac/institutes/grid.411613.0", 
          "name": [
            "Department of Pharmaceutical Technology, School of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, 790-8578, Matsuyama, Ehime, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakamoto", 
        "givenName": "Takatoshi", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1248/cpb.51.772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009372048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.49.1412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011251687"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1773-2247(09)50019-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014570189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.c12-00743", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016445537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2008.01.062", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027841941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4164/sptj.20.558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033579383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4164/sptj.20.558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033579383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-014-9598-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045901943", 
          "https://doi.org/10.1208/s12248-014-9598-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.aca.2005.09.070", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048171359"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1248/cpb.47.678", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049461236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jddst.2017.03.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084086905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.xphs.2017.03.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084113130"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12249-017-0765-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084255458", 
          "https://doi.org/10.1208/s12249-017-0765-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12249-017-0765-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084255458", 
          "https://doi.org/10.1208/s12249-017-0765-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4164/sptj.54.90", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084454488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejps.2017.09.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091533147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2017.12.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099626184"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-05", 
    "datePublishedReg": "2019-05-01", 
    "description": "Direct powder compression is the simplest tablet manufacturing method. However, segregation occurs when the drug content is low. It is difficult to assure drug content uniformity in these cases. In this study, we evaluated microcrystalline cellulose (MCC) as a segregation inhibitor in pharmaceutical powders. We assessed the influence of MCC concentration and mixing time on the physical properties of tablets. The tablet formulation comprised acetaminophen, lactose hydrate, cornstarch, MCC (0%, 10%, or 20%), croscarmellose sodium, and magnesium stearate (Mg-St). All powders except Mg-St were premixed for 5, 15, or 25\u00a0min. Mg-St was then added and mixed for 5\u00a0min to prepare nine pharmaceutical powders. Flowability index and practical angle of internal friction were measured. Tablets were also prepared, and their weight variation, hardness, friability, disintegration time, and drug content variation were evaluated. MCC slightly decreased pharmaceutical powder flowability. Tablet hardness increased and disintegration time decreased with increasing MCC concentration. MCC mixed for \u2265\u200915\u00a0min also significantly lowered drug content variation. A contour plot was prepared to assess the effect of MCC concentration and mixing time on the physical properties of tablets. It was determined that tablets with 50-80\u00a0N hardness, \u2264\u20093.5\u00a0min disintegration time, and \u2264\u20093% drug content variation can be prepared when MCC concentration is 6.5-8.5% and the mixing time is 19-24\u00a0min. Therefore, MCC is effective as a segregation inhibitor, and the addition of MCC to tablet formulation improves drug content uniformity.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1208/s12249-019-1365-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1023420", 
        "issn": [
          "1530-9932"
        ], 
        "name": "AAPS PharmSciTech", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "name": "Utility of Microcrystalline Cellulose for Improving Drug Content Uniformity in Tablet Manufacturing Using Direct Powder Compression", 
    "pagination": "151", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2523ad471d85ec9f6d5fda17e54983a16dae8e71d76eacb42e4cb7497a5ea8d9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30903317"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100960111"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1208/s12249-019-1365-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112942613"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1208/s12249-019-1365-4", 
      "https://app.dimensions.ai/details/publication/pub.1112942613"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000364_0000000364/records_72859_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1208%2Fs12249-019-1365-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1365-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1365-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1365-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1208/s12249-019-1365-4'


 

This table displays all metadata directly associated to this object as RDF triples.

135 TRIPLES      21 PREDICATES      44 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1208/s12249-019-1365-4 schema:about anzsrc-for:09
2 anzsrc-for:0904
3 schema:author N855c9d30998044efb549c2180c6b5dab
4 schema:citation sg:pub.10.1208/s12248-014-9598-3
5 sg:pub.10.1208/s12249-017-0765-6
6 https://doi.org/10.1016/j.aca.2005.09.070
7 https://doi.org/10.1016/j.ejps.2017.09.017
8 https://doi.org/10.1016/j.ijpharm.2008.01.062
9 https://doi.org/10.1016/j.ijpharm.2017.12.011
10 https://doi.org/10.1016/j.jddst.2017.03.014
11 https://doi.org/10.1016/j.xphs.2017.03.005
12 https://doi.org/10.1016/s1773-2247(09)50019-6
13 https://doi.org/10.1248/cpb.47.678
14 https://doi.org/10.1248/cpb.49.1412
15 https://doi.org/10.1248/cpb.51.772
16 https://doi.org/10.1248/cpb.c12-00743
17 https://doi.org/10.4164/sptj.20.558
18 https://doi.org/10.4164/sptj.54.90
19 schema:datePublished 2019-05
20 schema:datePublishedReg 2019-05-01
21 schema:description Direct powder compression is the simplest tablet manufacturing method. However, segregation occurs when the drug content is low. It is difficult to assure drug content uniformity in these cases. In this study, we evaluated microcrystalline cellulose (MCC) as a segregation inhibitor in pharmaceutical powders. We assessed the influence of MCC concentration and mixing time on the physical properties of tablets. The tablet formulation comprised acetaminophen, lactose hydrate, cornstarch, MCC (0%, 10%, or 20%), croscarmellose sodium, and magnesium stearate (Mg-St). All powders except Mg-St were premixed for 5, 15, or 25 min. Mg-St was then added and mixed for 5 min to prepare nine pharmaceutical powders. Flowability index and practical angle of internal friction were measured. Tablets were also prepared, and their weight variation, hardness, friability, disintegration time, and drug content variation were evaluated. MCC slightly decreased pharmaceutical powder flowability. Tablet hardness increased and disintegration time decreased with increasing MCC concentration. MCC mixed for ≥ 15 min also significantly lowered drug content variation. A contour plot was prepared to assess the effect of MCC concentration and mixing time on the physical properties of tablets. It was determined that tablets with 50-80 N hardness, ≤ 3.5 min disintegration time, and ≤ 3% drug content variation can be prepared when MCC concentration is 6.5-8.5% and the mixing time is 19-24 min. Therefore, MCC is effective as a segregation inhibitor, and the addition of MCC to tablet formulation improves drug content uniformity.
22 schema:genre research_article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf Nb6601b6c000044ec8742591f03525cfe
26 Nfb82c185bccf47c48c550d8a1c9a2d9c
27 sg:journal.1023420
28 schema:name Utility of Microcrystalline Cellulose for Improving Drug Content Uniformity in Tablet Manufacturing Using Direct Powder Compression
29 schema:pagination 151
30 schema:productId N12737266a6a0469bac22c4315290f300
31 N2506163aed824f5ab55a7450cee7f497
32 N2cfa4eade5d34b99a5aeacf792e6bb30
33 N3cbd220404934b70ac5fba898a467257
34 N909e07873ae5469e889c3f9edb0f96f3
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112942613
36 https://doi.org/10.1208/s12249-019-1365-4
37 schema:sdDatePublished 2019-04-11T12:54
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher Ne297875409984e03b0f37487c6b47d2d
40 schema:url https://link.springer.com/10.1208%2Fs12249-019-1365-4
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N12737266a6a0469bac22c4315290f300 schema:name dimensions_id
45 schema:value pub.1112942613
46 rdf:type schema:PropertyValue
47 N2506163aed824f5ab55a7450cee7f497 schema:name doi
48 schema:value 10.1208/s12249-019-1365-4
49 rdf:type schema:PropertyValue
50 N2cfa4eade5d34b99a5aeacf792e6bb30 schema:name readcube_id
51 schema:value 2523ad471d85ec9f6d5fda17e54983a16dae8e71d76eacb42e4cb7497a5ea8d9
52 rdf:type schema:PropertyValue
53 N30d4aef741ca4d7a8344ea5a74601ee5 rdf:first N88647a696f224015a42cea0f8795e3ea
54 rdf:rest N3afb2cef99c1443882743d83570f83c3
55 N3afb2cef99c1443882743d83570f83c3 rdf:first Necb11c69fef0479589fb63b1b9f1c133
56 rdf:rest rdf:nil
57 N3cbd220404934b70ac5fba898a467257 schema:name pubmed_id
58 schema:value 30903317
59 rdf:type schema:PropertyValue
60 N4389a1cd22ef4b4e9884bf297c4a6695 rdf:first N8485b391e7d343e4a2bde887a8e4ac69
61 rdf:rest N30d4aef741ca4d7a8344ea5a74601ee5
62 N8485b391e7d343e4a2bde887a8e4ac69 schema:affiliation https://www.grid.ac/institutes/grid.411613.0
63 schema:familyName Tanaka
64 schema:givenName Chisato
65 rdf:type schema:Person
66 N855c9d30998044efb549c2180c6b5dab rdf:first Nd4ab2aba0f3749159d2f2b388112d800
67 rdf:rest N4389a1cd22ef4b4e9884bf297c4a6695
68 N88647a696f224015a42cea0f8795e3ea schema:affiliation https://www.grid.ac/institutes/grid.410714.7
69 schema:familyName Yuasa
70 schema:givenName Hiroshi
71 rdf:type schema:Person
72 N909e07873ae5469e889c3f9edb0f96f3 schema:name nlm_unique_id
73 schema:value 100960111
74 rdf:type schema:PropertyValue
75 Nb6601b6c000044ec8742591f03525cfe schema:issueNumber 4
76 rdf:type schema:PublicationIssue
77 Nd4ab2aba0f3749159d2f2b388112d800 schema:affiliation https://www.grid.ac/institutes/grid.411613.0
78 schema:familyName Nakamura
79 schema:givenName Shohei
80 rdf:type schema:Person
81 Ne297875409984e03b0f37487c6b47d2d schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 Necb11c69fef0479589fb63b1b9f1c133 schema:affiliation https://www.grid.ac/institutes/grid.411613.0
84 schema:familyName Sakamoto
85 schema:givenName Takatoshi
86 rdf:type schema:Person
87 Nfb82c185bccf47c48c550d8a1c9a2d9c schema:volumeNumber 20
88 rdf:type schema:PublicationVolume
89 anzsrc-for:09 schema:inDefinedTermSet anzsrc-for:
90 schema:name Engineering
91 rdf:type schema:DefinedTerm
92 anzsrc-for:0904 schema:inDefinedTermSet anzsrc-for:
93 schema:name Chemical Engineering
94 rdf:type schema:DefinedTerm
95 sg:journal.1023420 schema:issn 1530-9932
96 schema:name AAPS PharmSciTech
97 rdf:type schema:Periodical
98 sg:pub.10.1208/s12248-014-9598-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045901943
99 https://doi.org/10.1208/s12248-014-9598-3
100 rdf:type schema:CreativeWork
101 sg:pub.10.1208/s12249-017-0765-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084255458
102 https://doi.org/10.1208/s12249-017-0765-6
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1016/j.aca.2005.09.070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048171359
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1016/j.ejps.2017.09.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091533147
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1016/j.ijpharm.2008.01.062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027841941
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1016/j.ijpharm.2017.12.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099626184
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1016/j.jddst.2017.03.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084086905
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1016/j.xphs.2017.03.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084113130
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1016/s1773-2247(09)50019-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014570189
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1248/cpb.47.678 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049461236
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1248/cpb.49.1412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011251687
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1248/cpb.51.772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009372048
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1248/cpb.c12-00743 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016445537
125 rdf:type schema:CreativeWork
126 https://doi.org/10.4164/sptj.20.558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033579383
127 rdf:type schema:CreativeWork
128 https://doi.org/10.4164/sptj.54.90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084454488
129 rdf:type schema:CreativeWork
130 https://www.grid.ac/institutes/grid.410714.7 schema:alternateName Showa University
131 schema:name School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, 142-8555, Tokyo, Japan
132 rdf:type schema:Organization
133 https://www.grid.ac/institutes/grid.411613.0 schema:alternateName Matsuyama University
134 schema:name Department of Pharmaceutical Technology, School of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, 790-8578, Matsuyama, Ehime, Japan
135 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...